Sildenafil cream demonstrates safety, efficacy in phase 2b study for female sexual arousal disorder

Dr.

Is Viagra an Option for Female Sexual Dysfunction?

9 : Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). 10 : Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. 11 Guay, A., Munarriz, R., Jacobson, M.A., Talakoub, L., Goldstein, I., Traish, A. et-al: Androgen values in premenopausal women without sexual dysfunction. Presented at International Society for the Study of Women's Sexual Health, Vancouver, British Columbia, Canada, October 10–13, 2002 Google Scholar 13 : Development of a sexual function questionnaire for clinical trials of female sexual dysfunction.

How it Helps You Do It

J Womens Health Gend Based Med2002; 11: 277. 14 : The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction. 15 : Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med2002; 11: 367. 16 : Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. Zanotti clears up what Viagra does, and doesn’t do,

for women, and what options are available for you. Technically, yes, women can take Viagra

THE BIG “O” (OVERVIEW)

Regulatory Strategy for Sildenafil Cream, 3.6%: Next Steps The Company is working to align with the FDA on the Phase 3 study design. At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. We evaluated the efficacy and safety of sildenafil citrate in spontaneously or surgically postmenopausal women with female sexual arousal disorder (FSAD).

Key takeaways

Sildenafil (a 50 mg dose adjustable to 100 or 25 mg) was evaluated in a 12-week, double-blind, placebo controlled study in 202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy. Patients were excluded if emotional, relationship or historical abuse issues contributed significantly to sexual dysfunction. Primary end points were questions 2 (increased genital sensation during intercourse or stimulation) and 4 (increased satisfaction with intercourse and/or foreplay) from the Female Intervention Efficacy Index (FIEI). Secondary end points were the remaining questions from this index, the Sexual Function Questionnaire and sexual activity event log questions. Significant improvements in FIEI questions 2 (p = 0.017) and 4 (p = 0.015) were noted with sildenafil compared with placebo. (also known by the generic name sildenafil).

But the U.S.

• Sildenafil is a medication primarily used to treat erectile dysfunction in men.
• Women sildenafil is an off-label use aimed at improving female sexual arousal.
• Clinical trials are ongoing to assess efficacy of sildenafil for women.
• Side effects of sildenafil may include headaches, flushing, and nasal congestion.
• Women may experience increased blood flow and libido with sildenafil.
• Proper dosage and medical consultation are essential before use.

Food and Drug Administration (FDA) hasn’t

How Viagra Works

All participants had a main diagnosis of FSAD and may have also had concomitant sexual dysfunction diagnoses or symptoms including decreased desire, orgasmic dysfunction, and genital pain. Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a non-drug and placebo run-in period: Compared Sildenafil Cream vs. placebo used in patients’ home setting. Co-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).

Related medical questions

Secondary endpoint: measured change in the number of satisfactory sexual events Exploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments. Sildenafil Cream-treated group showed meaningful improvement in the co‑primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.1 Post-hoc analyses showed that Sildenafil Cream met the Ph2b co-primary endpoint (SFQ28-arousal domain patient reported outcome (PRO)) and demonstrated clinically meaningful benefit in patients who have FSAD or FSAD with concomitant decreased desire. Secondary and exploratory endpoints saw these patients report meaningful improvement in arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Read more about the Phase 2b clinical study here. approved it for use by women.

Why is this medicine prescribed?

For women with FSAD without concomitant sildenafil 5mg for sale hypoactive sexual desire disorder (HSDD) sildenafil was associated with significantly greater improvement in 5 of 6 FIEI items compared with placebo (p <0.02). No significant improvements were shown for women with concomitant HSDD. Most adverse events were mild to moderate with headache, flushing, rhinitis, nausea and visual symptoms reported most frequently. Sildenafil was effective and well tolerated in postmenopausal women with FSAD without concomitant HSDD or contributory emotional, relationship or historical abuse issues. All patients had protocol specified estradiol and free testosterone concentrations or were receiving estrogen and/or androgen replacement therapy.

Bupropion (Wellbutrin)

1 : Report of the International Consensus Development Conference on Female Sexual Dysfunction: definitions and classifications. 2 : Female sexual arousal disorder: new insights. 5 : Development of human and rabbit vaginal smooth muscle cell cultures: effects of vasoactive agents on intracellular levels of cyclic nucleotides. 7 : Sildenafil, a novel effective oral therapy for male erectile dysfunction. 8 : Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. “Viagra is approved for treating

• Sildenafil may help women with conditions like arousal disorder, but evidence varies.
• There is ongoing research into safe, effective female-specific doses of sildenafil.
• Side effects experienced by women can include dizziness, nausea, or visual disturbances.
• Consumption of alcohol while on sildenafil can increase side effect risks.
• Female sexual dysfunction can have psychological, hormonal, and physical causes.
• Sildenafil is not a cure-all; proper diagnosis is important for targeted treatment.

erectile dysfunction, nothing more,” Dr.

What side effects can this medicine cause?

17 : Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. 18 : Effects of ovariectomy and estrogen and androgen treatment on sildenafil-mediated changes in female genital blood flow and vaginal lubrication in the animal model. 19 : The role of androgen in the maintenance of sexual functioning in oophorectomized women. 20 : Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. From the Department of Urology, University of California-Los Angeles Medical Center, Los Angeles, California, Departments of Obstetrics and Gynecology, and Psychiatry, Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois, and Pfizer Global Research and Development, Groton, Connecticut, and Sandwich, United Kingdom The little blue pill might help with physical arousal, but there are better treatments for low libido in women Image content: This image is available to view online.

How should sildenafil for women be used?

Woman researching viagra on her cell phone Concerns about sex drive and sexual performance are extremely common in women. Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Ob/Gyn Salena Zanotti, MD, sees it all the time in her practice: “It’s probably one of the top questions I get asked, and it’s common in adults of all ages.” We know that Viagra® can help men perform between the sheets. Zanotti clarifies.

• The legality of women using sildenafil varies by country and local regulations.
• Lifestyle modifications can complement medication for better sexual health outcomes.
• Women with diabetes may have different responses to sildenafil therapy.
• The stigma surrounding female sexual dysfunction can hinder treatment seeking.
• Advances in research are aimed at developing female-specific ED medications.
• Open discussions with physicians are essential for safe and effective treatments.

“It hasn’t proven to be

• Doctors may prescribe sildenafil off-label for women based on individual assessment.
• Patient education about realistic expectations is essential when using sildenafil.
• Sildenafil’s mechanism involves enhancing nitric oxide signaling in blood vessels.
• Women with liver or kidney problems need careful evaluation before sildenafil use.
• Viagra was initially tested for women before focusing on men’s erectile issues.
• Alternative options like vaginal lubricants are also common for female sexual problems.

the answer for sexual dysfunction outside

How Does Viagra Affect Women?

Sildenafil Cream, 3.6% is an investigational proprietary topical formulation of sildenafil being developed as a first-in-category option for women for the treatment of FSAD. Unlike the oral formulations of PDE-5 inhibitors, Sildenafil Cream is applied locally to the vaginal tissue and is designed to facilitate vasodilation and increased blood flow directly to the genital tissue to improve the physical arousal response symptoms commonly associated with FSAD while avoiding systemic side effects observed with oral formulations of sildenafil. Phase 1 and Phase 2a Clinical Studies, Previously Completed In a Phase 1 clinical study in 20 healthy post-menopausal women, topical sildenafil cream was safe and well tolerated at clinically relevant doses, and study subjects reported favorable product characteristics: easy to use and readily absorbed. In a Phase 2a study in women with FSAD (15 pre-menopausal and 16 post-menopausal), Sildenafil Cream increased measurable blood flow to the genital tissue compared to placebo cream. Further, data from a thermography study in healthy women demonstrated significantly greater increases in genital temperature after administration of Sildenafil Cream compared to placebo cream, indicating a positive impact on genital blood flow during the 30-minute testing session, with statistical separation from placebo within the first 15 minutes after dosing.

Similar content being viewed by others

We also completed a content validity study designed to identify and document the genital arousal symptoms that are the most important and relevant to women with FSAD. The findings of this study helped facilitate alignment with the FDA on acceptable efficacy endpoints for the Phase 2b RESPOND study and a future Phase 3 program. The Phase 2b study was an exploratory study to evaluate a number of primary endpoints and secondary endpoints as well as to identify a target patient population for Sildenafil Cream, 3.6%. The Phase 2b clinical study was designed as a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD). Study participants used Sildenafil Cream and placebo cream over 12 weeks in their home setting, following both a non-drug and placebo cream run-in period. of that.” Viagra works by

increasing blood flow to the genitals.